FMS Stock Recent News

Fresenius Medical Care AG FMS on Tuesday introduced a strategic roadmap — FME Reignite — aimed at revitalizing its core business, driving innovation and reshaping its organizational culture.

EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive' rather than negative.

FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovation The Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plans Profitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 margins FME25+ savings target expanded by EUR 300 million to EUR 1.05 billion by 2027 Annual capex of EUR 0.8 to 1.0 billion for core business to drive profitable growth and to support innovation Further optimization of capital structure with lowered net leverage ratio target band of 2.5x to 3.0x Commitment to return excess capital to shareholders: 30-40 percent dividend payout2 plus initial share buyback program of EUR 1 billion BAD HOMBURG, Germany and LONDON , June 17, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, today unveiled its new FME Reignite strategy

The world's largest dialysis specialist Fresenius Medical Care said, ahead of its capital markets day on Tuesday, that it plans to embark on a 1 billion euros ($1.16 billion) share buyback programme.

Thermal purification run on Lac Knife concentrate material produced and characterized by AETC has resulted in 99.9992 wt. % C purity – laying the foundation for the transition into the nuclear spec material purity OTTAWA, ON , June 12, 2025 /PRNewswire/ - Focus Graphite Advanced Materials Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") is pleased to announce that recent thermal purification testing completed by American Energy Technologies Company ("AETC") has successfully refined Lac Knife flake graphite concentrate to a purity level of 99.999 wt.

FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.

Fresenius (FMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Updated 5008X CAREsystem with Additional Features Receives FDA 510(k) Clearance Company announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering  high-volume hemodiafiltration therapy to dialysis patients Introducing the 5008X CAREsystem and hemodiafiltration kidney replacement therapy is a key pillar of the company's growth strategy BAD HOMBURG, Germany , June 4, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second phase of the company's efforts to introduce high-volume hemodiafiltration (HVHDF) kidney replacement therapy across the United States. The company last week received FDA 510(k) clearance for the updated version of its new, hemodiafiltration-capable 5008X CAREsystem with additional features, a key benchmark enabling the next steps in the company's broader commercialization efforts across the U.S. later this year, followed by a full-

Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care's commitment to improving patient outcomes. Top Abstract recognition for "Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort," presented in the "Dialysis" category.

Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's history Excellent progress in the company's transformation and turnaround plans continues to strengthen the foundation for sustainable, profitable growth In 2024, organic revenue growth1 was 4 percent, and operating income increased by 18 percent on an outlook base2, coming in at the upper end of the company's outlook The company is well positioned for double digit earnings growth in 2025, translating to an 11-12 percent margin BAD HOMBURG, Germany , May 22, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, continuously executed its strategic plan during the 2024 fiscal year. The success of this transformation is strengthening the foundation for sustainable, profitable growth — both now and in the future.